Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies – Executive summary

Auteurs-es

  • Andrea Kokorovic
  • Alan I. So
  • Hosam Serag
  • Christopher French
  • Robert J. Hamilton
  • Jason P. Izard
  • Jasmir G. Nayak
  • Fréderic Pouliot
  • Fred Saad
  • Bobby Shayegan
  • Armen Aprikian
  • Ricardo A. Rendon

DOI :

https://doi.org/10.5489/cuaj.7357

Mots-clés :

ADT, prostate cancer, CV risk, bone health, HRQOL

Résumé

Androgen deprivation therapy (ADT) plays an important role in the contemporary management of prostate cancer (PCa) across various stages of the disease. While ADT remains a highly effective treatment for PCa, it is not curative, and its use is associated with significant adverse events that span across various organ systems.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Téléchargements

Publié-e

2021-05-31

Comment citer

Kokorovic, A. ., So, A. I. ., Serag, H. ., French, C. ., Hamilton, R. J. ., Izard, J. P. ., … Rendon, R. A. . (2021). Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies – Executive summary. Canadian Urological Association Journal, 15(6), 159–61. https://doi.org/10.5489/cuaj.7357

Numéro

Rubrique

CUA Guideline